Accupril

Heart Attack, Congestive Heart Failure, Diabetic Nephropathies + 2 more

Treatment

3 FDA approvals

20 Active Studies for Accupril

What is Accupril

Quinapril

The Generic name of this drug

Treatment Summary

Quinapril is a medication used to treat high blood pressure and heart failure. It works by blocking an enzyme in the body that increases blood pressure. It was approved by the FDA in 1991 and a combination tablet with hydrochlorothiazide was approved in 1999. ACE inhibitors, of which quinapril is one, are often prescribed as the first line of treatment for high blood pressure.

Quinapril Hydrochloride

is the brand name

image of different drug pills on a surface

Accupril Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Quinapril Hydrochloride

Quinapril

1991

190

Approved as Treatment by the FDA

Quinapril, also known as Quinapril Hydrochloride, is approved by the FDA for 3 uses including Congestive Heart Failure (CHF) and Hypertensive disease .

Congestive Heart Failure (CHF)

Used in combination with other therapies

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Congestive Heart Failure

Used in combination with other therapies

Effectiveness

How Accupril Affects Patients

Quinapril is a drug used to treat high blood pressure or to help with heart failure. It is considered to be relatively safe and produces long lasting effects when a proper dose is taken daily.

How Accupril works in the body

Angiotensin II tightens coronary blood vessels and increases oxygen consumption. Over time this can cause cell enlargement and more cell growth in the vessels. Angiotensin II also triggers the production of a substance which increases the risk of blood clots. Quinaprilat stops the conversion of angiotensin I to angiotensin II, reducing the amount of this substance in the body. This lowers the risk of blood clots, especially after a heart attack.

When to interrupt dosage

The prescribed quantity of Accupril is contingent upon the determined affliction, including Diabetic Nephropathy, Heart Attack and Left Ventricular Dysfunction. The amount of dosage will differ in relation to the delivery approach (e.g. Tablet, film coated or Tablet, film coated - Oral) detailed in the table below.

Condition

Dosage

Administration

Heart Attack

, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Ventricular Dysfunction, Left

, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Diabetic Nephropathies

, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Hypertensive disease

, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Congestive Heart Failure

, 5.0 mg, 10.0 mg, 20.0 mg, 40.0 mg

, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Warnings

Accupril Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Angioedema

Do Not Combine

There are 20 known major drug interactions with Accupril.

Common Accupril Drug Interactions

Drug Name

Risk Level

Description

Amifostine

Major

Quinapril may increase the hypotensive activities of Amifostine.

Azathioprine

Major

The risk or severity of myelosuppression, anemia, and severe leukopenia can be increased when Quinapril is combined with Azathioprine.

Lithium carbonate

Major

The serum concentration of Lithium carbonate can be increased when it is combined with Quinapril.

Lithium citrate

Major

The serum concentration of Lithium citrate can be increased when it is combined with Quinapril.

Lithium hydroxide

Major

The serum concentration of Lithium hydroxide can be increased when it is combined with Quinapril.

Accupril Toxicity & Overdose Risk

The lowest toxic dose of quinapril in rats has been found to be 3541mg/kg and in mice is 1739mg/kg. Those who overdose on quinapril may experience dangerously low blood pressure. Since quinapril binds strongly to proteins, it cannot be removed from the bloodstream by dialysis. Patients should be treated with fluids to restore their normal blood pressure.

image of a doctor in a lab doing drug, clinical research

Accupril Novel Uses: Which Conditions Have a Clinical Trial Featuring Accupril?

111 trials are presently investigating the potential of Accupril to provide relief for Left Ventricular Dysfunction, Heart Attack and Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Congestive Heart Failure

11 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Ventricular Dysfunction, Left

0 Actively Recruiting

Diabetic Nephropathies

0 Actively Recruiting

Heart Attack

23 Actively Recruiting

Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1, Phase 3

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Accupril Reviews: What are patients saying about Accupril?

5

Patient Review

8/10/2012

Accupril for Kidney Disease from Diabetes

I've had type 1 diabetes for 37 years, and my kidneys were leaking protein. So my doctor put me on Accupril. I didn't have high blood pressure, so I started with 2.5mg, and now I'm up to 5mg without any major issues. I have developed a cough that sometimes interferes with my eating and makes me a bit breathless, but I'm not too worried about it. Considering I was only expected to live 10 more years when I was first diagnosed, I'm doing pretty well!

5

Patient Review

7/9/2013

Accupril for High Blood Pressure

For the first four hours or so, this drug effectively lowers my blood pressure. However, after that time frame it becomes ineffective and my blood pressure returns to normal.

5

Patient Review

7/21/2013

Accupril for High Blood Pressure

I took this medication for a decade without any issues. However, about a year ago I developed a dry cough that wouldn't go away. Once I changed medications, the cough disappeared.

5

Patient Review

8/1/2014

Accupril for High Blood Pressure

After taking this medication for a decade or more, many people in the midsouth region began having serious side effects. Some even needed to go to the emergency room.

4.7

Patient Review

12/26/2009

Accupril for Kidney Disease from Diabetes

4.7

Patient Review

2/10/2011

Accupril for High Blood Pressure

4.3

Patient Review

11/13/2013

Accupril for High Blood Pressure

I was on this medication for a decade and saw great results. Recently, my readings have started going up again, though I'm not sure if that's because I switched to a different medication (my insurance refused to cover the cost of Accupril) or not. I'm currently on three different medications and experiencing some side effects, but I'm going to tell my doctor that I want to go back on Accupril.

4

Patient Review

9/12/2012

Accupril for High Blood Pressure

I took 20 mg of this medication for one year. My blood pressure was only slightly lowered to around 155/84. I always felt tired and needed to take it at bedtime. Additionally, there was slight swelling of my hands and the area around my eyes. I stopped taking it and tried other blood pressure medications but their side effects were worse so now I'm back on Accupril.

4

Patient Review

10/25/2011

Accupril for High Blood Pressure

4

Patient Review

4/25/2014

Accupril for High Blood Pressure

I was feeling really bad and I thought I was going to die. My heart was racing and then slowing down and I felt like harming people. This treatment helped me a lot.

4

Patient Review

1/30/2014

Accupril for High Blood Pressure

This medication has helped me a lot with my dry cough.

4

Patient Review

12/17/2013

Accupril for High Blood Pressure

This treatment is effective and helped me.

4

Patient Review

11/11/2014

Accupril for High Blood Pressure

I had been on Accupril or quinapril 10 for a long time without any issues. It kept my blood pressure under control. However, last month I experienced swelling of my tongue and was rushed to the hospital. I now know that this is a side effect of the drug. It can happen at any time and can stay in your system for up to six weeks. I have since changed my BP medication.

2.7

Patient Review

12/20/2009

Accupril for High Blood Pressure

2.7

Patient Review

1/25/2010

Accupril for High Blood Pressure

2.7

Patient Review

3/20/2012

Accupril for High Blood Pressure

I take 80mg of accupril 2 times a day when I wake up on Mondays. My blood pressure is 160 over 80.

2

Patient Review

5/18/2011

Accupril for High Blood Pressure

2

Patient Review

7/2/2014

Accupril for High Blood Pressure

I had a cough and low sodium levels.

1.7

Patient Review

2/4/2014

Accupril for High Blood Pressure

This medication has effectively kept my blood pressure in check.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about accupril

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the generic name for Accupril?

"Quinapril is used for the treatment of high blood pressure and congestive heart failure.

Quinapril is an ACE inhibitor used for treating high blood pressure and congestive heart failure."

Answered by AI

What type of drug is Accupril?

"Quinapril is a medication used to treat heart failure and hypertension. It is classified as an ACE inhibitor, meaning that it works by relaxing blood vessels and allowing blood to flow more easily."

Answered by AI

What is the difference between Accupril and lisinopril?

"Zestril lowers blood pressure effectively and protects kidney function. Accupril lowers blood pressure, reduces the risk of heart attack and stroke, and protects kidneys, making it a good choice for people with diabetes or mild-to-moderate kidney disease."

Answered by AI

What is the medication Accupril used for?

"It is also used to treat heart failure and to improve survival after a heart attack."

Answered by AI

Clinical Trials for Accupril

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Have you considered Accupril clinical trials?

We made a collection of clinical trials featuring Accupril, we think they might fit your search criteria.
Go to Trials
Image of Mumford Professional Centre in Halifax, Canada.

Remote Monitoring for Cardiovascular Disease

18+
All Sexes
Halifax, Canada

The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program. The wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program. The primary objectives of this study are to: 1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not. 2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by: 1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates, 2. Evaluating change in patient bloodwork outcomes, 3. Measuring change is physical ability, 4. Analyzing changes in eating behaviours, and 5. Examining quality of life using validated tools. 3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by: 1. Assessing device adherence 2. Reviewing patient feedback survey, and 3. Determining if clinician team were able to access and interpret data collected throughout the program The secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program. This research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.

Waitlist Available
Has No Placebo

Mumford Professional Centre

Nicholas B Giacomantonio, Medical Doctor

Corsano Health B.V.

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Accupril clinical trials?

We made a collection of clinical trials featuring Accupril, we think they might fit your search criteria.
Go to Trials
Image of St Boniface Hospital in Winnipeg, Canada.

Remote Home Monitoring for Heart Attack

18+
All Sexes
Winnipeg, Canada

Heart attacks are one of the top causes of death in Canada, with over 2,100 cases treated each year in Manitoba. Even though hospital care has improved, the period after going home is still risky. Many patients feel anxious and unsure about their recovery, and without enough support, they often end up back in the emergency department (ED). This is an even bigger challenge for people in rural areas, where getting follow-up care can be much harder. Filling these gaps is important to help patients get better and to reduce stress on the healthcare system. In a previous study, the investigators found that extra support made a big difference: only 8% of participants using a digital health tool returned to the ED within 30 days, compared to 22% of participants without it. Now, the investigators want to expand this study across Manitoba to see if digital health tools can help more people recover safely at home. The investigators will compare two types of follow-up care: education only versus education with extra support (like symptom tracking and virtual appointments). The investigators will look at how this affects hospital visits, mental well-being, and healthcare costs. The goal is to create a better support system for people after a heart attack, leading to healthier recoveries, less strain on hospitals, and better care for Manitobans - no matter where they live.

Waitlist Available
Has No Placebo

St Boniface Hospital

Image of Baystate Medical Center in Springfield, United States.

Consent Approaches for Heart Disease Rehabilitation

18+
All Sexes
Springfield, MA

Cardiac Rehabilitation is a lifestyle and exercise program for patients with heart disease. Cardiac Rehabilitation is strongly recommended in guidelines, but only 30% of eligible patients attend. New strategies are needed to help more patients attend cardiac rehabilitation. In this study, the investigators will see if using an $50 incentive, case management, text messages, and physical activity coaching combined into a single intervention will help more patients attend cardiac rehabilitation. In preparation for a larger trial, patients will also be randomly assigned to four different ways of seeking their permission to be in a research study. The investigators will see if these approaches affect how many people participate in the research project. The two main goals of this study is to understand: 1. If the consent approach type impacts participation rates in the research study 2. If the multi-component intervention (case management, financial incentives, text messages, and physical activity coaching) improves cardiac rehabilitation participation within 3 months.

Waitlist Available
Has No Placebo

Baystate Medical Center

Quinn R Pack, MD, MSc

Have you considered Accupril clinical trials?

We made a collection of clinical trials featuring Accupril, we think they might fit your search criteria.
Go to Trials